Health Communication and Informatics Research Branch, Behavioral Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, 9609 Medical Center Drive, 20850, Rockville, MD, USA.
ICF Next, Rockville, MD, USA.
J Behav Med. 2023 Apr;46(1-2):366-376. doi: 10.1007/s10865-022-00304-7. Epub 2022 Mar 19.
Due to cancer survivors' increased vulnerability to complications from COVID-19, addressing vaccine hesitancy and improving vaccine uptake among this population is a public health priority. However, several factors may complicate efforts to increase vaccine confidence in this population, including the underrepresentation of cancer patients in COVID-19 vaccine trials and distinct recommendations for vaccine administration and timing for certain subgroups of survivors. Evidence suggests vaccine communication efforts targeting survivors could benefit from strategies that consider factors such as social norms, risk perceptions, and trust. However, additional behavioral research is needed to help the clinical and public health community better understand, and more effectively respond to, drivers of vaccine hesitancy among survivors and ensure optimal protection against COVID-19 for this at-risk population. Knowledge generated by this research could also have an impact beyond the current COVID-19 pandemic by informing future vaccination efforts and communication with cancer survivors more broadly.
由于癌症幸存者更容易受到 COVID-19 并发症的影响,因此解决这一人群对疫苗的犹豫态度并提高疫苗接种率是公共卫生的重点。然而,有几个因素可能会使增加这一人群对疫苗的信心变得复杂,包括癌症患者在 COVID-19 疫苗试验中的代表性不足,以及某些亚组幸存者在疫苗接种管理和时间上的独特建议。有证据表明,针对幸存者的疫苗传播工作可以从考虑社会规范、风险认知和信任等因素的策略中受益。然而,还需要进一步的行为研究来帮助临床和公共卫生界更好地理解和更有效地应对幸存者对疫苗的犹豫态度的驱动因素,确保这一高危人群对 COVID-19 的最佳保护。这项研究产生的知识不仅可以通过为未来的疫苗接种工作和更广泛地与癌症幸存者沟通提供信息,而且还可以超越当前的 COVID-19 大流行产生影响。